TB-500 (Thymosin Beta-4 Fragment)

Also referred to as Thymosin Beta-4 fragment, TB4 Fragment.

Status: Investigational. TB-500 is not an FDA-approved drug product, and it is not itself the full naturally occurring protein. It is a research-market name for a synthetic peptide sequence related to thymosin beta-4, a protein studied for its role in actin regulation and cell migration. "TB-500" is a designation that arose in the research-chemical marketplace rather than an approved or standardized pharmaceutical product name, and the labelling on products sold under that name is not independently verified.

TB-500 is the name used in the research-chemical marketplace for a synthetic peptide related to a short active region of thymosin beta-4, a naturally occurring protein involved in cell movement and structural signalling within cells. It is not an FDA-approved drug product, and "TB-500" itself is not a scientifically standardized name, which means products sold under it are not independently verified to contain what their labels claim. Most available evidence comes from animal studies of tissue and vascular signalling rather than controlled human trials. Patients researching it should distinguish between the biology of thymosin beta-4 as studied in labs and the unregulated commercial products marketed as TB-500.

What it is

Thymosin beta-4 is a small protein found throughout the body that plays a role in regulating actin, a structural protein involved in cell shape and movement. TB-500 refers to a synthetic peptide fragment intended to mimic part of that protein's active region, sold commercially as a research chemical. Because "TB-500" is not a regulated pharmaceutical designation, there is no standardized manufacturing specification behind the name, and the actual content of products using it can vary between suppliers.

Why people ask about it

Interest usually comes from athletes and people recovering from soft-tissue injuries who have encountered claims online linking TB-500 to recovery signalling. The naming itself causes confusion, since people often assume TB-500 is simply purified thymosin beta-4 when it is a distinct, unregulated commercial product. Patients frequently want clarity on what is actually known about thymosin beta-4 biology versus what is asserted about TB-500 specifically.

Proposed mechanism

Research on thymosin beta-4 has proposed a role in regulating actin polymerization, which affects how cells move and change shape during processes like wound closure and vascular formation. Animal studies have proposed that this could translate into effects on angiogenesis and cell migration relevant to soft-tissue and vascular models. These proposed mechanisms are derived from cell and animal work characterizing the native protein, not from pharmacology studies of the specific commercial peptide sold as TB-500. It is not established that a synthetic fragment behaves identically to the full native protein in human tissue.

What researchers have studied

Cell-culture studies of actin regulation and cell migration
Animal models of vascular formation (angiogenesis)
Animal models of corneal and dermal wound closure
Rodent models of cardiac tissue injury
Structural and biochemical characterization of thymosin beta-4

Human evidence

No controlled human clinical trials of the commercial product sold as TB-500 have been identified.
Human research on the native thymosin beta-4 protein itself is limited and does not directly validate claims made about TB-500 products.
Because product identity is not independently regulated, any anecdotal human reports cannot be tied with confidence to a verified, consistent substance.
No human safety or exposure data specific to the commercial peptide exist in the peer-reviewed literature.

Preclinical evidence

Rodent studies have reported effects on wound closure timelines in skin injury models.
Animal models have reported thymosin beta-4 involvement in blood vessel formation after induced injury.
Cell-culture work has characterized the protein's role in actin-based cell movement.
Rodent cardiac injury models have reported changes in markers of tissue response.
These findings are limited to laboratory and animal contexts and have not been confirmed in human trials of the commercial peptide.

What is not yet known

Whether the commercial TB-500 product reliably matches the biology studied for native thymosin beta-4.
Whether any human benefit exists at any exposure level.
The consistency, purity, and identity of products sold under the TB-500 name across suppliers.
Long-term safety of repeated exposure in people.
How this substance might interact with other medications or conditions.
Whether regulatory scrutiny of this substance will change as data accumulates.

Regulatory status and access

TB-500 is not offered as an individually prescribable product; where it appears in physician-directed discussion, it is only as one component a physician may consider within a broader formulation. Compounding elsewhere does not equal FDA approval, and no claim here should be read as availability. Ask about current availability. A physician determines medical appropriateness only after a full evaluation.

Known and potential risks

No verified human safety profile exists for the specific commercial peptide sold as TB-500.
Because the name is not a regulated designation, product identity, purity, and sterility from unregulated suppliers cannot be confirmed.
Injection-related risks apply to any unregulated injectable research product, including contamination.
Interaction risk with other medications or conditions is essentially unstudied.
Marketing claims often blur the line between native thymosin beta-4 research and the unregulated commercial product, which can mislead purchasing decisions.
Absence of oversight means adverse effects, if they occur, are unlikely to be systematically captured or reported.

Cautions and who may not be a candidate

Pregnancy and breastfeeding, given the absence of human safety data.
Active or suspected malignancy, given unresolved questions about cell proliferation signalling.
Undiagnosed musculoskeletal, vascular, or cardiac symptoms that have not been medically evaluated.
Known hypersensitivity to peptide compounds generally.
Concurrent use of other unregulated research compounds without physician oversight.
Use as a substitute for an evaluated, evidence-based recovery plan.

Questions to discuss with a physician

How does the biology of thymosin beta-4 differ from claims made about commercial TB-500 products?
What does the lack of human trial data mean for the specific concern I'm asking about?
How would you assess the quality or legitimacy of a product marketed under this name?
What evidence-based options exist for the recovery goal I have in mind?
What symptoms would mean I should stop and seek care right away?
Is there a legitimate research pathway through which this could ever become available to me?

Frequently asked questions

Is TB-500 FDA-approved?

No. TB-500 is not an FDA-approved drug product, and it is not a standardized pharmaceutical name. It refers to a synthetic peptide sold in the research-chemical marketplace.

Does GOAL.MD sell TB-500?

This page is educational only. It does not describe a product for sale. Ask about current availability, and appropriateness is determined only by a physician after evaluation.

Is TB-500 the same thing as thymosin beta-4?

TB-500 is intended to relate to an active fragment of thymosin beta-4, but it is a distinct commercial product name rather than a verified, standardized version of the native protein.

Why is it called TB-500 if that isn't a scientific name?

The designation originated in the research-chemical marketplace as a commercial label rather than through a formal pharmaceutical naming or approval process.

Has TB-500 been studied in people?

No controlled human trials of the commercial TB-500 product have been identified. Related research on the native protein exists but does not validate claims specific to commercial TB-500.

What has TB-500 been studied for in animals?

Animal and cell studies have looked at wound closure, vascular formation, and cell migration processes linked to thymosin beta-4 biology.

Is TB-500 safe?

A reliable human safety profile has not been established, and unregulated sourcing adds additional uncertainty about product identity and purity.

Can a doctor prescribe TB-500?

It is not offered as a standalone prescription product. A physician can discuss the underlying biology and any legitimate research context that might be relevant.

How do I know if a product labelled TB-500 actually contains what it claims?

There is no independent regulatory verification of these products, so label claims cannot be confirmed through standard pharmaceutical oversight.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.